Skip to main
MYGN
MYGN logo

Myriad Genetics (MYGN) Stock Forecast & Price Target

Myriad Genetics (MYGN) Analyst Ratings

Based on 30 analyst ratings
Hold
Strong Buy 20%
Buy 13%
Hold 47%
Sell 20%
Strong Sell 0%

Bulls say

Myriad Genetics Inc. has demonstrated strong growth in its Pharmacogenomics segment, with a 14% year-over-year increase in 2024, highlighting the robust demand for their GeneSight product, which experienced a 23% growth during the same period. The prenatal testing segment, particularly Prequel and Foresight tests, also showed positive momentum with a combined 12% growth in 4Q24 and 17% growth for the full fiscal year 2024, indicating strong market demand that is expected to accelerate in 2025. Furthermore, the anticipated launch of an expanded hereditary cancer screening test in the latter half of 2025, along with potential regulatory benefits from updates in carrier screening guidelines, positions Myriad Genetics to capitalize on sustainable growth and capture additional market share in a consolidating market.

Bears say

Myriad Genetics has faced significant challenges leading to a negative outlook, primarily highlighted by the recent loss of a private payer's reimbursement for GeneSight and changes in NCCN guideline language, which have negatively impacted near-term revenues. The company’s FY25 revenue guidance of $840M-$860M falls short of both analyst and consensus expectations, further raising concerns about its ability to accelerate organic growth and maintain relationships with payors, which are critical for its operational performance. Additionally, ongoing risks such as regulatory challenges, competition, and the potential for continued price erosion could impede future profitability and market share gains, suggesting that Myriad Genetics may struggle to meet revised expectations set by previous leadership.

Myriad Genetics (MYGN) has been analyzed by 30 analysts, with a consensus rating of Hold. 20% of analysts recommend a Strong Buy, 13% recommend Buy, 47% suggest Holding, 20% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Myriad Genetics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Myriad Genetics (MYGN) Forecast

Analysts have given Myriad Genetics (MYGN) a Hold based on their latest research and market trends.

According to 30 analysts, Myriad Genetics (MYGN) has a Hold consensus rating as of Jun 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $24.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $24.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Myriad Genetics (MYGN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.